These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3612896)

  • 21. The effect of activated charcoal on the bioavailability of piroxicam in man.
    Laufen H; Leitold M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):48-52. PubMed ID: 3957490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of size and frequency of oral doses of charcoal on theophylline clearance.
    Park GD; Radomski L; Goldberg MJ; Spector R; Johnson GF; Quee CK
    Clin Pharmacol Ther; 1983 Nov; 34(5):663-6. PubMed ID: 6627827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits.
    el-Sayed YM; Hasan MM
    J Pharm Pharmacol; 1990 Aug; 42(8):538-41. PubMed ID: 1981579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of charcoal-drug ratio on antidotal efficacy of oral activated charcoal in man.
    Olkkola KT
    Br J Clin Pharmacol; 1985 Jun; 19(6):767-73. PubMed ID: 4027120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of activated charcoal on rifampicin absorption in man.
    Orisakwe OE; Dioka CE; Okpogba AN; Orish CN; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):51-4. PubMed ID: 9239805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of orally administered activated charcoal on intestinal dialysis of intravenously administered M79175, an aldose reductase inhibitor, in rats.
    Arimori K; Mishima M; Iwaoku R; Nakano M
    J Pharmacobiodyn; 1987 Jun; 10(6):243-9. PubMed ID: 3118006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple-dose activated charcoal and enhancement of systemic drug clearance: summary of studies in animals and human volunteers.
    Chyka PA
    J Toxicol Clin Toxicol; 1995; 33(5):399-405. PubMed ID: 7650764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of charcoal on the absorption and elimination of the antiepileptic drugs lamotrigine and oxcarbazepine.
    Keränen T; Sorri A; Moilanen E; Ylitalo P
    Arzneimittelforschung; 2010; 60(7):421-6. PubMed ID: 20712131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of the effect of repeated doses of oral activated charcoal on salicylate elimination.
    Ho JL; Tierney MG; Dickinson GE
    J Clin Pharmacol; 1989 Apr; 29(4):366-9. PubMed ID: 2723125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enteral exsorption of acetaminophen after intravenous injection in rats: influence of activated charcoal on this clearance path.
    Eyer F; Jung N; Neuberger H; Schulz R; Steiner K; Ladstetter B; Poethko T; Henke J; Zilker T
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):163-71. PubMed ID: 17697035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of activated charcoal administration on acetylcysteine serum levels in humans.
    North DS; Peterson RG; Krenzelok EP
    Am J Hosp Pharm; 1981 Jul; 38(7):1022-4. PubMed ID: 7258201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers.
    Winslade NE; Adelman MH; Evans EJ; Schentag JJ
    Antimicrob Agents Chemother; 1987 Apr; 31(4):605-9. PubMed ID: 3606064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of activated charcoal on absorption of tolbutamide and valproate in man.
    Neuvonen PJ; Kannisto H; Hirvisalo EL
    Eur J Clin Pharmacol; 1983; 24(2):243-6. PubMed ID: 6404636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of kaolin-pectin and activated charcoal for inhibition of aspirin absorption.
    Juhl RP
    Am J Hosp Pharm; 1979 Aug; 36(8):1097-8. PubMed ID: 484570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seromucosal transport of intravenously administered carbamazepine is not enhanced by oral doses of activated charcoal in rats.
    Eyer F; Jung N; Neuberger H; Witte A; Poethko T; Henke J; Zilker T
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):337-46. PubMed ID: 18248517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acceleration of the body clearance of phenobarbital by oral activated charcoal.
    Berg MJ; Berlinger WG; Goldberg MJ; Spector R; Johnson GF
    N Engl J Med; 1982 Sep; 307(11):642-4. PubMed ID: 7050705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of the surface area of activated charcoal on theophylline clearance.
    Park GD; Spector R; Goldberg MJ; Johnson GF; Feldman R; Quee CK
    J Clin Pharmacol; 1984 Jul; 24(7):289-92. PubMed ID: 6480875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-compartment comparison of gentamicin and tobramycin in normal volunteers.
    Adelman M; Evans E; Schentag JJ
    Antimicrob Agents Chemother; 1982 Nov; 22(5):800-4. PubMed ID: 7181489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration.
    Laine K; Kivistö KT; Pelttari S; Neuvonen PJ
    Pharmacol Toxicol; 1996 Nov; 79(5):270-3. PubMed ID: 8936562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers.
    al-Shareef A; Buss DC; Shetty HG; Ali N; Routledge PA
    Br J Clin Pharmacol; 1997 Jan; 43(1):109-11. PubMed ID: 9056061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.